Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers

Drug

Mitiglinide (10 mg/tablet, lot no.14032011, expiration: 29/02/2016) was manufactured by Suzhong Pharma Co. Ltd., Jiangsu, China.

Subjects

The study was approved by the Ethics Committee of the Affiliated Hospital of Nanjing University of Chinese Medicine (IRB#2014NL-020-02). Eighteen healthy male volunteers participated in this study, with average age of 24 (ranging from 18 to 40) and average weight of 67.5 kg (ranging from 56 to 80 kg). All volunteers went through thorough physical examinations and routine laboratory evaluations, including haematology, serum chemistry, virus and urinalysis. None of the volunteers in this study took any drugs which would have affected this study for at least 3 months beforehand. The limitation of our study lies in the fact that subjects were excluded from health problems including drug or alcohol abuse, and the abnormalities in the experiment. All volunteers were informed of the purpose and possible risks before the test and they could withdraw from the test any time for any reason. Signed informed consent was obtained before any trial-related activities.

Experimental design

Subjects were fasted for 10 h before the experiment. An intravenous cannula was inserted into the forearm vein to collect blood samples at time zero. The test group took the agent with 250 mL of water after baseline sampling. All subjects were accommodated in the care unit in the Affiliated Hospital of Nanjing University of Chinese Medicine during the test. Blood samples were taken at 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.75, 1, 1.5, 2, 3 h after drug administration, centrifuged immediately for 10 min at 3000 rpm, and stored at −80 °C until analysis.

Analysis of the plasma drug concentrations and blood glucose levels

Plasma mitiglinide concentration was determined by the modification of the methods of Yu and Takanohashi [9, 12]. A 1200 HPLC system (Agilent technologies, Palo Alto, CA, USA) coupled with a triple-quadrupole tandem API 4000 mass spectrometer (AB/MDS-Sciex, Concord, Ontario, Canada) were used for analysis. Instrumental control and data processing was performed by the Analyst software (version 1.4.2). The LC separation was performed on an Agilent Zorbax SB-C₁₈column (150 mm × 2.1 mm I.D., 3.5 μm, Agilent Technologies, Wilmington, DE, USA) with a security guard column (12.5 mm × 2.1 mm I.D., 5 μm, Agilent Zorbax SB-C₁₈, DE, USA). The mobile phase consisted of methanol and deionized water (v:v, 60:40) containing 0.1% formic acid at a flow rate of 0.30 mL/min, the autosampler temperature was set at 15 °C and the column temperature was set at 30 °C. A MS detector with electrospray ionization (ESI) interface was used in our experiment and the positive ion mode was selected for quantitative analysis. Quantitation was detected by the multi-reaction-monitoring (MRM) mode of transitions of m/z 316.2 → 298.2 for Mitiglinide, m/z 318.2 → 120.2 for Nateglinide. The optimized conditions used for the ESI⁺ source were set as follows: capillary voltage 5.5 KV; turbo heater temperature 600 °C; curtain gas (CUR) 40 psi; collision activation dissociation (CAD) 8 psi; declustering potential (DP) 81 V; collision energy (CE) 23 eV for mitiglinide and 29 eV for IS respectively. Blood glucose concentration was examined by the glucose oxidase method with the use of an autoanalyzer (TosohG8, Japan).

Statistical analysis

Graphical and all other statistical analyses, including the evaluation outputs, were performed within the Phoenix platform [13].

Pharmacokinetic/pharmacodynamic model and data analysis

A two-compartment linked with E_max PK-PD model was implemented by maximizing the log-likelihood using the first-order conditional estimation (FOCE) method of the Phoenix NLME software (Pharsight Corp, St. Louis, Missouri, United States of America). Pharmacokinetics and pharmacodynamics values of mitiglinide were modelled sequentially. The models were established as a series of equations, describing the relationship between plasma medicine and glucose. The equations were solved numerically and fitted to the data with Phoenix NLME [11]. Plasma concentration of mitiglinide was used for the PK analysis. The two-compartment model for oral administration was established by the least-squares method, and the pharmacokinetic parameters including V, V2, CL and CL₂ were also calculated. The amounts of mitiglinide and plasma concentrations in the central compartment (C) were determined and calculated by the distribution volume for the central compartment (V). The two-compartment model as shown in Fig. 1, and the overall PK model could be described as Eqs. (1) to (11) as below:

$$ \mathrm{dAa}/\mathrm{dt}=\hbox{-} {\mathrm{Ka}}^{\ast }\ \mathrm{Aa} $$

(1)

$$ \mathrm{dA}1/\mathrm{dt}={\mathrm{Ka}}^{\ast }\ \mathrm{Aa}\hbox{-} {\mathrm{CL}}^{\ast }\ \mathrm{C}\hbox{-} \mathrm{C}\mathrm{L}{2}^{\ast }\ \left(\mathrm{C}\hbox{-} \mathrm{C}2\right) $$

(2)

$$ \mathrm{dA}2/\mathrm{dt}=\mathrm{CL}{2}^{\ast }\ \left(\mathrm{C}\hbox{-} \mathrm{C}2\right) $$

(3)

$$ \mathrm{C}=\mathrm{A}1/\mathrm{V} $$

(4)

$$ \mathrm{C}2=\mathrm{A}2/\mathrm{V}2 $$

(5)

$$ \mathrm{Ka}={\mathrm{tvKa}}^{\ast }\ \exp \left(\upeta \mathrm{Ka}\right) $$

(6)

$$ \mathrm{V}={\mathrm{tvV}}^{\ast }\ \exp \left(\upeta \mathrm{V}\right) $$

(7)

$$ \mathrm{V}2=\mathrm{tvV}2 $$

(8)

$$ \mathrm{CL}=\mathrm{tvCL} $$

(9)

$$ \mathrm{CL}2=\mathrm{tvCL}{2}^{\ast }\ \exp \left(\upeta \mathrm{CL}2\right) $$

(10)

$$ \mathrm{Tlag}={\mathrm{tvTlag}}^{\ast }\ \exp \left(\upeta \mathrm{Tlag}\right) $$

(11)

A means the amount of mitiglinide, A₁ and A₂ suggest the amounts of drug in the central and peripheral compartments respectively. The concentrations of mitiglinide in the central and peripheral compartment are represented as C and C₂ respectively. The elimination clearances of the drug in the central and peripheral compartments are represented as CL and CL₂ respectively. TV indicates the typical value of population mean, and η indicates the inter-individual variation. PK parameters were obtained by simultaneously fitting the plasma concentration data after oral administration of mitiglinide (10 mg) to volunteers using the 2-compartment PK model (Table 1).

Where E is the level of glucose in the plasma, E₀ is the blood glucose maintained at a certain level in absence of the drug. C is the plasma concentration in the central compartment and Ce represents the plasma concentration in the effect compartment. K_eo represents the glucose disappearance rate constant. TV represents the typical value of the population mean and η means the inter-individual variation, and the inter-individual variation for parameters with high shrinkage value (>0.5) were not included in the model.

Pharmacokinetics

Mitiglinide could reduce the early-phase insulin release and promote the controlling of the postprandial glucose levels with its ability to fasten insulin secretagogue [17]. The characteristic of mitiglinide of anti-hyperglycemic can take effect more rapidly compared with sulphonylureas. The fast release of insulin within a few minutes was due to the rapid absorption rate of mitiglinide after oral administration [18]. In the 90% confidence internal of geometric mean ratios, mitiglinide reached its peak plasma concentration (C _max) and AUC_last, which represented the area under the plasma concentration-time curve from time zero to the time of the last measurable concentration, were observed as 0.9694 (0.8120, 1.1573) and 0.8951 (0.8440, 0.9494), respectively [19]. Mitiglinide could bind to the SUR and activate it in the pancreatic β-cells, which was considered as the mechanism of the drug underlying the therapeutic effect [20, 21]. In the present study, mitiglinide was given by oral administration and the short elimination half-life, t _1/2 (h) was 1.69. Therefore, the fast absorption in the first 2 h may be caused by the binding of the free form drug to the SUR. The total clearance (CL/F) was 7.79 mL/h in our study, which is comparable to rat (0.83 mL/h) in previous studies [22].

PK-PD modeling of glucose lowering effects

The characters of PK behaviors and its influences to the values of plasma glucose levels have been studied in several hypoglycemic drugs [23, 24]. Toshiyuki Takanohashi et al. reported the pk-pd. modeling methodology to describe the rapidity therapeutic effect of mitiglinide by using the receptor-binding-dissociation in rats [12]. However, model of inhaled glucose in healthy humans has not been published previously. Phoenix platform is the commonly used software to investigate PK/PD characters depending on the 2-compartment model [25, 26]. Our study analyzed the effects of mitiglinide on glucose lowering after a single oral dose. The shorter duration action of mitiglinide and the decreasing glucose levels in plasma was described by a two-compartment model followed by the least-squares method. The fitting results were adequate, and the efficacy of the drug has been appropriated proposed by the empirical biexponential equation. Furthermore, the model is flexible for the concentration and efficiency of the drug. The T _max (h) of mitiglinide was 0.25 (0.17–0.50) in our study and the glucose decrease reached its maximum.

Although mitiglinide is a commonly used and effective drug for diabetes mellitus in clinic, its side effects and the interaction remain to be studied further. A recent investigation shows that mitiglinide treatment could significantly decrease plasma fibroblast growth factor levels, which would have various effects on pancreatic islets [27]. Our results may illustrate the physiological effects of mitiglinide and its relationship with plasma concentration. Different kinds of indirect response models can be used to explain the pk-pd. property of drug. In our study, we investigated glucose disappearance and mitiglinide concentration levels in plasma by building the pk-pd. modeling. The CWRES distribution of the final model uniformed on both sides of the zero line, and the value ranged between 2 and −2 indicating the minor differences in prediction model. The result of our research could describe the drug’s pharmacological action. The results of our experiment are benefit for study designs and appropriate dosage selection of diabetes mellitus in clinical trials.